The analysis of effects on insulin resistance and atherosclerotic risk factors before and after the treatment in patients with primary aldosteronism (PA)
Not Applicable
- Conditions
- Primary aldosteronism
- Registration Number
- JPRN-UMIN000002196
- Lead Sponsor
- Faculty of Life Sciences, Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Glucocorticoid-remediable aldosteronism (GRA)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Insulin resistance 2) Inflamatory cytokine 3) markers of organ damage
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link primary aldosteronism to insulin resistance and atherosclerosis?
How does PA treatment compare to standard-of-care in improving metabolic and cardiovascular outcomes?
Are there specific biomarkers for predicting treatment response in PA patients with insulin resistance?
What adverse events are associated with PA interventions and how are they managed clinically?
What drug classes or combination therapies show promise in addressing PA-related atherosclerotic risk factors?